Gilder Gagnon Howe & Co’s Passage Bio PASG Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio PASG Stock Details PASG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-2,074	Closed	-$1.13M	–	349
2020 Q2	$1.13M	Buy	+2,074	New	+$933K	0.01%	233

Other funds holding PASG

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HCM

Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Gilder Gagnon Howe & Co's PASG Position: Q3 2020 in Review

Gilder Gagnon Howe & Co sold out of Passage Bio (PASG) in Q3 2020, closing a stake of 2,074 shares — an estimated $1.13M sold.

Gilder Gagnon Howe & Co first reported a position in PASG in Q2 2020 and held it in 1 quarter. The position peaked at $1.13M in Q2 2020. 70 funds tracked by Wall St. Rank hold PASG as of Q3 2020.

Gilder Gagnon Howe & Co reported no remaining Passage Bio position as of Q3 2020 after selling out during the quarter.
Gilder Gagnon Howe & Co sold 2,074 Passage Bio shares in Q3 2020, an estimated $1.13M.
Gilder Gagnon Howe & Co first reported a position in Passage Bio in Q2 2020 and held it in 1 quarter.
Gilder Gagnon Howe & Co's Passage Bio position peaked at $1.13M in Q2 2020.
70 funds tracked by Wall St. Rank held Passage Bio as of Q3 2020.

Based on Gilder Gagnon Howe & Co's 13F filing for Q3 2020, filed 16 Nov 2020.